The Rheumatologist
COVID-19 News
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Ankylosing Spondylitis Resource Center
    • Gout Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Systemic Lupus Erythematosus Resource Center
      • Rheumatoid Arthritis Resource Center
      • Gout Resource Center
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / Rheumatology Drug Updates: Infliximab Biosimilar Cross Reacts to Infliximab Antibodies

Rheumatology Drug Updates: Infliximab Biosimilar Cross Reacts to Infliximab Antibodies

August 11, 2016 • By Michele B. Kaufman, PharmD, BCGP

  • Tweet
  • Email
Print-Friendly Version / Save PDF

Researchers randomized 879 patients in a 3:1 ratio via a double-blind method to receive 400 mg certolizumab pegol at Weeks 0, 2 and 4 and then 200 mg certolizumab pegol every two weeks through Week 52 along with MTX (n=660), or placebo and MTX (n=219; either 15 mg or 25 mg weekly). The primary efficacy endpoint was the proportion of patients in sustained remission (DAS [ESR] <2.6) at both Weeks 40 and 52. The secondary endpoint was the proportion of patients with sustained low disease activity (DAS28 [ESR] ≤3.2) at both Weeks 40 and 52.

You Might Also Like
  • Infliximab Biosimilar Cross Reacts to Infliximab Antibodies; Plus Treat-to-Target Strategy Promising for Treating RA with bDMARDs
  • Rheumatology Drug Updates: Infliximab Biosimilar Gets FDA Approval & More
  • Remicade Antibodies Cross-React to Biosimilars
Explore This Issue
August 2016
Also By This Author
  • Factors that Influence Biologic Therapy Choices for Patients with Rheumatoid Arthritis

Study authors caution: Patients on infliximab who have developed antibodies to infliximab should not be switched to an infliximab biosimilar.

At Week 52, 29% vs. 15% (P<0.001) of certolizumab pegol plus MTX and MTX-only treated patients, respectively, achieved sustained remission. Additionally, 44% vs. 29% (P<0.001) of certolizumab pegol plus MTX and MTX-only treated patients, respectively, achieved sustained low disease activity. For certolizumab pegol plus MTX-treated patients, there was significantly greater inhibition of radiographic progression and physical functioning improvement vs. MTX plus placebo-treated patients. Of all randomized patients, 143 of placebo plus MTX-treated patients completed Week 52 and 500 certolizumab pegol plus MTX-treated patients completed Week 52.

Adverse events and serious adverse events were similar between both treatment groups. Infection occurred more frequently in the certolizumab pegol plus MTX-treated patients. Serious infection rates were similar between the two treatment groups. Two deaths occurred in the certolizumab pegol-treated group: one from a stroke not believed to be medication related, and one from a disseminated, mycobacterium infection thought to be medication related. One death also occurred in the MTX plus placebo-treated group that was not thought to be treatment related.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

Michele B. Kaufman, PharmD, CGP, RPh, is a freelance medical writer based in New York City and a pharmacist at New York Presbyterian Lower Manhattan Hospital.

References

  1. Ruiz-Argüello B, Maguregu A, Ruiz del Agua A, et al. Antibodies to infliximab in Remicade-treated rheumatic patients show identical reactivity towards biosimilar CT-P13. Ann Rheum Dis. 2016 Mar 10. pii: annrheumdis-2015-208684. doi: 10.1136/annrheumdis-2015-208684. [Epub ahead of print]
  2. Lampropoulos CE, Orfanos P, Manoussakis M, et al. Efficacy of treat-to-target biologic therapy in patients with rheumatoid arthritis compared to delayed initiation of biologics: A real world study. Ann Rheum Dis. 2016;75(Suppl2):193. doi: 10.1136/annrheumdis-2016-eular.1187
  3. Emery P, Bingham III CO, Burmester GR, et al. Certolizumab pegol in combination with dose-optimised methotrexate in DMARD-naive patients with early, active rheumatoid arthritis with poor prognostic factors: 1-year results from C-EARLY, a randomised, double-blind, placebo-controlled Phase III study. Ann Rheum Dis. 2016 May 10. pii: annrheumdis-2015-209057. doi: 10.1136/annrheumdis-2015-209057. [Epub ahead of print].
ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

Pages: 1 2 3 | Single Page

Filed Under: Biologics & Biosimilars, Conditions, Drug Updates Tagged With: Antibodies, biologic, biolosimilar, disease-modifying antirheumatic drug, DMARD, drug, FDA, infliximab, Rheumatoid arthritis, rheumatology, Safety, therapy, Treatment, updateIssue: August 2016

You Might Also Like:
  • Infliximab Biosimilar Cross Reacts to Infliximab Antibodies; Plus Treat-to-Target Strategy Promising for Treating RA with bDMARDs
  • Rheumatology Drug Updates: Infliximab Biosimilar Gets FDA Approval & More
  • Remicade Antibodies Cross-React to Biosimilars
  • Antibodies to Remicade Cross-React with Biosimilar Remsima

American College of Rheumatology

Visit the official website for the American College of Rheumatology.

Visit the ACR »

Rheumatology Research Foundation

The Foundation is the largest private funding source for rheumatology research and training in the U.S.

Learn more »

Simple Tasks

Learn more about the ACR’s public awareness campaign and how you can get involved. Help increase visibility of rheumatic diseases and decrease the number of people left untreated.

Visit the Simple Tasks site »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2021 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)

loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.
This site uses cookies: Find out more.